肺癌患者-话题@MedSci

#肺癌患者#

303篇内容 | 5533人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1990778, encodeId=82d31990e78ac, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=以脑转移为首发的肺癌患者的临床特点及预后影响因素分析, objectType=article, longId=221266, objectId=f8c72212663c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f8c72212663c, replyNumber=0, likeNumber=94, createdTime=2022-02-03, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f8c72212663c, moduleTitle=以脑转移为首发的肺癌患者的临床特点及预后影响因素分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f8c72212663c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990767, encodeId=24751990e670c, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=J Thorac Oncol：Brigatinib（布加替尼）vs Crizotinib（克唑替尼）治疗未治ALK阳性晚期非小细胞肺癌患者的疗效：3期临床研究ALTA-1L最终分析结果, objectType=article, longId=217316, objectId=e44421e31653, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e44421e31653, replyNumber=0, likeNumber=87, createdTime=2022-08-03, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e44421e31653, moduleTitle=J Thorac Oncol：Brigatinib（布加替尼）vs Crizotinib（克唑替尼）治疗未治ALK阳性晚期非小细胞肺癌患者的疗效：3期临床研究ALTA-1L最终分析结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e44421e31653)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990756, encodeId=382a1990e5691, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189, objectType=article, longId=212750, objectId=8752212e509b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8752212e509b, replyNumber=0, likeNumber=90, createdTime=2021-12-12, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8752212e509b, moduleTitle=Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8752212e509b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990779, encodeId=1e2d1990e79bc, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=林根教授谈新冠肺炎疫情逐步控制下肺癌患者的诊疗建议，推荐合适的患者接受口服抗肿瘤药物治疗, objectType=article, longId=221294, objectId=313a221294fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=313a221294fd, replyNumber=0, likeNumber=120, createdTime=2022-01-02, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=313a221294fd, moduleTitle=林根教授谈新冠肺炎疫情逐步控制下肺癌患者的诊疗建议，推荐合适的患者接受口服抗肿瘤药物治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=313a221294fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990746, encodeId=c3991990e467a, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=创新药物可及性不断提升，助力中国肺癌患者生存获益, objectType=article, longId=205921, objectId=8bc5205921d6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8bc5205921d6, replyNumber=0, likeNumber=95, createdTime=2021-05-14, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8bc5205921d6, moduleTitle=创新药物可及性不断提升，助力中国肺癌患者生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8bc5205921d6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990748, encodeId=66fa1990e4831, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=2020世界肺癌大会：LDCT筛查对检出非吸烟肺癌患者的有效性, objectType=article, longId=206728, objectId=70fc206e28e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=70fc206e28e2, replyNumber=0, likeNumber=75, createdTime=2021-03-16, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=70fc206e28e2, moduleTitle=2020世界肺癌大会：LDCT筛查对检出非吸烟肺癌患者的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=70fc206e28e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990742, encodeId=64631990e4297, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=J Thromb Haemost：ALK和EGFR突变型肺癌患者血栓栓塞风险分析, objectType=article, longId=204723, objectId=251b204e2375, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=251b204e2375, replyNumber=0, likeNumber=82, createdTime=2021-04-03, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=251b204e2375, moduleTitle=J Thromb Haemost：ALK和EGFR突变型肺癌患者血栓栓塞风险分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=251b204e2375)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990745, encodeId=39491990e4545, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=Eur Radiol：如何无创性准确非小细胞肺癌患者前纵隔淋巴结是否发生转移？, objectType=article, longId=205663, objectId=ce0020566300, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce0020566300, replyNumber=0, likeNumber=80, createdTime=2021-01-24, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce0020566300, moduleTitle=Eur Radiol：如何无创性准确非小细胞肺癌患者前纵隔淋巴结是否发生转移？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce0020566300)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990753, encodeId=71b31990e53df, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=J Thorac Oncol：尼拉帕利一线维持治疗中国铂敏感的广泛期小细胞肺癌患者的3期临床试验结果, objectType=article, longId=210730, objectId=22a4210e30f6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22a4210e30f6, replyNumber=0, likeNumber=113, createdTime=2022-01-26, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22a4210e30f6, moduleTitle=J Thorac Oncol：尼拉帕利一线维持治疗中国铂敏感的广泛期小细胞肺癌患者的3期临床试验结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=22a4210e30f6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990758, encodeId=f04a1990e5825, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=Lancet Respirat：Savolitinib在METex14跳跃变异阳性的中国肺癌患者中的疗效可期！, objectType=article, longId=213129, objectId=c62f21312916, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c62f21312916, replyNumber=0, likeNumber=78, createdTime=2021-11-09, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c62f21312916, moduleTitle=Lancet Respirat：Savolitinib在METex14跳跃变异阳性的中国肺癌患者中的疗效可期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c62f21312916)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990741, encodeId=29881990e4132, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=JCO：BLOOM研究——Osimertinib在EGFRm和LM非小细胞肺癌患者中的应用, objectType=article, longId=204599, objectId=0719204599a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0719204599a7, replyNumber=0, likeNumber=84, createdTime=2021-07-23, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0719204599a7, moduleTitle=JCO：BLOOM研究——Osimertinib在EGFRm和LM非小细胞肺癌患者中的应用, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0719204599a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990755, encodeId=50e41990e5587, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=ASCO2021:Patritumab Deruxtecan在EGFR抑制剂耐药、EGFR突变的非小细胞肺癌患者中产生持久反应, objectType=article, longId=212480, objectId=b2a22124805f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2a22124805f, replyNumber=0, likeNumber=127, createdTime=2022-02-13, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2a22124805f, moduleTitle=ASCO2021:Patritumab Deruxtecan在EGFR抑制剂耐药、EGFR突变的非小细胞肺癌患者中产生持久反应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2a22124805f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990761, encodeId=89181990e61b4, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验, objectType=article, longId=213612, objectId=25b221361280, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=25b221361280, replyNumber=0, likeNumber=66, createdTime=2022-02-01, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=25b221361280, moduleTitle=Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=25b221361280)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990765, encodeId=40f51990e652a, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=Nat Med：抗PD-1耐药转移性肺癌患者肿瘤浸润淋巴细胞治疗效果何如？, objectType=article, longId=215717, objectId=cc41215e1761, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cc41215e1761, replyNumber=0, likeNumber=135, createdTime=2022-07-10, rootId=0, userName=柳叶一刀, userId=778d36, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cc41215e1761, moduleTitle=Nat Med：抗PD-1耐药转移性肺癌患者肿瘤浸润淋巴细胞治疗效果何如？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cc41215e1761)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990752, encodeId=2f8c1990e5297, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=III期临床研究CheckMate -816结果发布：欧狄沃®（纳武利尤单抗）联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善肿瘤病理完全缓解, objectType=article, longId=209763, objectId=515e209e63ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=515e209e63ce, replyNumber=0, likeNumber=98, createdTime=2022-01-08, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=515e209e63ce, moduleTitle=III期临床研究CheckMate -816结果发布：欧狄沃®（纳武利尤单抗）联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善肿瘤病理完全缓解, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=515e209e63ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990740, encodeId=b73f1990e4035, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=Brit J Cancer：二甲双胍与肺癌患者生存率的关系, objectType=article, longId=204050, objectId=203e20405015, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=203e20405015, replyNumber=0, likeNumber=83, createdTime=2021-08-15, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=203e20405015, moduleTitle=Brit J Cancer：二甲双胍与肺癌患者生存率的关系, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=203e20405015)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990759, encodeId=c9401990e59e0, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=Nat Commun：Notch信号通路影响复发性小细胞肺癌患者对免疫检查点阻断治疗的疗效, objectType=article, longId=213470, objectId=1c222134e0e8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1c222134e0e8, replyNumber=0, likeNumber=79, createdTime=2022-02-12, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1c222134e0e8, moduleTitle=Nat Commun：Notch信号通路影响复发性小细胞肺癌患者对免疫检查点阻断治疗的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1c222134e0e8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990738, encodeId=31451990e3862, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=Clin Lung Cancer：Atezolizumab可有效治疗日本广泛期小细胞肺癌患者，且耐受性良好, objectType=article, longId=201761, objectId=5d9d201e6149, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5d9d201e6149, replyNumber=0, likeNumber=90, createdTime=2020-10-12, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5d9d201e6149, moduleTitle=Clin Lung Cancer：Atezolizumab可有效治疗日本广泛期小细胞肺癌患者，且耐受性良好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5d9d201e6149)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990747, encodeId=a6e31990e474f, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=WCLC 2020：Datopotamab deruxtecan和Enhertu在晚期非小细胞肺癌患者中显示出有希望的临床活性, objectType=article, longId=206512, objectId=763d20651203, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=763d20651203, replyNumber=0, likeNumber=103, createdTime=2021-12-12, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=763d20651203, moduleTitle=WCLC 2020：Datopotamab deruxtecan和Enhertu在晚期非小细胞肺癌患者中显示出有希望的临床活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=763d20651203)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1990754, encodeId=5f861990e542b, content=<a href='/topic/show?id=5739822223f' target=_blank style='color:#2F92EE;'>#肺癌患者#</a>, objectTitle=Br J Cancer：安罗替尼（Anlotinib）：小细胞肺癌患者的三线或后续治疗药物, objectType=article, longId=211714, objectId=6de3211e1448, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6de3211e1448, replyNumber=0, likeNumber=89, createdTime=2021-12-05, rootId=0, userName=gds2009, userId=f612331, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6de3211e1448, moduleTitle=Br J Cancer：安罗替尼（Anlotinib）：小细胞肺癌患者的三线或后续治疗药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6de3211e1448)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

肺癌患者

2020-05-29

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

以脑转移为首发的肺癌患者的临床特点及预后影响因素分析

2022-02-03

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

J Thorac Oncol：Brigatinib（布加替尼）vs Crizotinib（克唑替尼）治疗未治ALK阳性晚期非小细胞肺癌患者的疗效：3期临床研究ALTA-1L最终分析结果

2022-08-03

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

Ann Oncol：帕博利珠单抗（pembrolizumab）联合培美曲塞+铂类治疗转移性非鳞状非小细胞肺癌患者的疗效和安全性：KEYNOTE-189

2021-12-12

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

林根教授谈新冠肺炎疫情逐步控制下肺癌患者的诊疗建议，推荐合适的患者接受口服抗肿瘤药物治疗

2022-01-02

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

创新药物可及性不断提升，助力中国肺癌患者生存获益

2021-05-14

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

2020世界肺癌大会：LDCT筛查对检出非吸烟肺癌患者的有效性

2021-03-16

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

J Thromb Haemost：ALK和EGFR突变型肺癌患者血栓栓塞风险分析

2021-04-03

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

Eur Radiol：如何无创性准确非小细胞肺癌患者前纵隔淋巴结是否发生转移？

2021-01-24

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

J Thorac Oncol：尼拉帕利一线维持治疗中国铂敏感的广泛期小细胞肺癌患者的3期临床试验结果

2022-01-26

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

Lancet Respirat：Savolitinib在METex14跳跃变异阳性的中国肺癌患者中的疗效可期！

2021-11-09

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

JCO：BLOOM研究——Osimertinib在EGFRm和LM非小细胞肺癌患者中的应用

2021-07-23

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

ASCO2021:Patritumab Deruxtecan在EGFR抑制剂耐药、EGFR突变的非小细胞肺癌患者中产生持久反应

2022-02-13

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

Cancer Commun：贝伐珠单抗生物类似物LY01008对比贝伐珠单抗(Avastin)一线治疗中国不可切除、转移或复发的非鳞状非小细胞肺癌患者的疗效和安全性:一项多中心、随机、双盲III期试验

2022-02-01

柳叶一刀 (审核中...)

前往app查看评论内容

#肺癌患者#

Nat Med：抗PD-1耐药转移性肺癌患者肿瘤浸润淋巴细胞治疗效果何如？

2022-07-10

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

III期临床研究CheckMate -816结果发布：欧狄沃®（纳武利尤单抗）联合化疗作为可切除非小细胞肺癌患者新辅助治疗，可显著改善肿瘤病理完全缓解

2022-01-08

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

Brit J Cancer：二甲双胍与肺癌患者生存率的关系

2021-08-15

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

Nat Commun：Notch信号通路影响复发性小细胞肺癌患者对免疫检查点阻断治疗的疗效

2022-02-12

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

Clin Lung Cancer：Atezolizumab可有效治疗日本广泛期小细胞肺癌患者，且耐受性良好

2020-10-12

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

WCLC 2020：Datopotamab deruxtecan和Enhertu在晚期非小细胞肺癌患者中显示出有希望的临床活性

2021-12-12

gds2009 (审核中...)

前往app查看评论内容

#肺癌患者#

Br J Cancer：安罗替尼（Anlotinib）：小细胞肺癌患者的三线或后续治疗药物

2021-12-05

科室
- - 订阅+
  - 更多科室
工具
服务